Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Anika Therapeutics (NQ: ANIK )

25.33 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 28, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 25.33
Bid (Size) 10.19 (1)
Ask (Size) 40.27 (1)
Prev. Close 25.33
Today's Range 25.33 - 25.33
52wk Range 16.54 - 28.67
Shares Outstanding 14,828,456
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Anika Therapeutics Inc.
Via GlobeNewswire
Peeling Back The Layers: Exploring Anika Therapeutics Through Analyst Insights
Via Benzinga

Performance

YTD
+11.78%
+11.78%
1 Month
-1.25%
-1.25%
3 Month
-1.44%
-1.44%
6 Month
+11.78%
+11.78%
1 Year
-2.95%
-2.95%

More News

Read More
Anika Enters into Cooperation Agreement with Caligan Partners
From Anika Therapeutics Inc.
Via GlobeNewswire
ANIK Stock Earnings: Anika Therapeutics Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Anika Therapeutics: Q4 Earnings Insights
Via Benzinga
Earnings Outlook For Anika Therapeutics
Via Benzinga
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Anika Therapeutics Inc.
Via GlobeNewswire
Anika to Issue First Quarter 2024 Financial Results on Wednesday, May 8, 2024
From Anika Therapeutics Inc.
Via GlobeNewswire
Anika to Participate in the 23rd Annual Needham Virtual Healthcare Conference
From Anika Therapeutics Inc.
Via GlobeNewswire
Earnings Scheduled For March 13, 2024
Via Benzinga
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Anika Therapeutics Inc.
Via GlobeNewswire
Anika to Issue Fourth Quarter and Year-End 2023 Financial Results on Wednesday, March 13, 2024
From Anika Therapeutics Inc.
Via GlobeNewswire
Anika Highlights Its Recently Launched Integrity™ Implant System and RevoMotion™ Reverse Shoulder Arthroplasty System Along with Other Key Regenerative Products During the 2024 AAOS Annual Meeting
From Anika Therapeutics Inc.
Via GlobeNewswire
Anika Announces First Surgeries Performed using the Integrity™ Implant System, a Regenerative Hyaluronic Acid-Based Patch System for Rotator Cuff Repairs, Commencing Limited Market Release
From Anika Therapeutics Inc.
Via GlobeNewswire
Anika to Participate in Upcoming Investor Conferences
From Anika Therapeutics Inc.
Via GlobeNewswire
Anika to Issue Third Quarter 2023 Financial Results on Thursday, November 2, 2023
From Anika Therapeutics Inc.
Via GlobeNewswire
Anika Announces the Full Market Release of the RevoMotion™ Reverse Shoulder Arthroplasty System during the 2023 Orthopaedic Summit: Evolving Technologies (OSET) Annual Meeting
From Anika Therapeutics Inc.
Via GlobeNewswire
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Anika Therapeutics Inc.
Via GlobeNewswire
Anika to Participate in the Sidoti Small Cap Virtual Investor Conference
From Anika Therapeutics Inc.
Via GlobeNewswire
Airbnb, Blackstone Rise On News They'll Join S&P 500 Index
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
3 Sorry Penny Stocks to Sell in August Before It’s Too Late
Via InvestorPlace
Anika Receives 510(k) Clearance for Integrity™ Implant System, a Regenerative Hyaluronic Acid-Based Patch System for Augmentation of Rotator Cuff Repairs
From Anika Therapeutics Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 14, 2023
Via Benzinga
Anika to Issue Second Quarter 2023 Financial Results on Tuesday, August 8, 2023
From Anika Therapeutics Inc.
Via GlobeNewswire
Anika Showcases Highly Differentiated Joint Preservation and Restoration Portfolio at the 2023 AOSSM Annual Meeting
From Anika Therapeutics Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.